Eugia US Manufacturing LLC gets 10 observations from USFDA for East Windsor facility

The United States Food and Drug Administration (US FDA) conducted a Pre-Approval Inspection (PAI) at new injectable facility of Eugia US Manufacturing LLC (a step-down wholly owned subsidiary of Aurobindo Pharma Ltd.), situated at East Windsor, New Jersey, USA from December 11 to December 22, 2023.

The inspection closed with 10 observations. The observations are procedural in nature and will be responded to within the stipulated time. The plant is yet to start commercial operations.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1066.15 as compared to the previous close of Rs. 1092.10. The total number of shares traded during the day was 102857 in over 4519 trades.

The stock hit an intraday high of Rs. 1100.00 and intraday low of 1063.50. The net turnover during the day was Rs. 111009195.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 EugiaUSManufacturingLLC 10Observations USFDA PAI InjectableFacility